Biotech Values

[dewophile]

FOB's are not yet ripe in my view - need to wait for the final FDA guidance before embarking on an expensive program.

sandoz has said they have 8 or so FOBs in development, and teva is already running a trial, so if mnta doesn't want to be left behind they had better get going (most accept that one trial - at least initially - will be needed even before final guidance is issued)

If this turns out to be correct (going it alone on 118) I suspect the market will not like it much.

i agree. the only scenario which might make sense is if mnta states very specifically they have partner(s) in waiting pending a successful 2b in a specific trial setting. the most bullish scenario would be to go straight to a registrational trial with a partner, and needing the cash up front to secure their share of trial cost (i may be in fantasy land here)